4D Molecular Therapeutics, Inc. 2024-2025 Proxy Voting Records

Description as filed by funds: Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Charles Theuer, M.D., Ph.D.

4D Molecular Therapeutics, Inc.’s own tally for this item (“Elect Director: Charles P. Theuer, M.D., Ph.D.”): 27,285,806 for, 4,985,609 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 8,401,540 for, 343,583 withheld.

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

Description as filed by funds: Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Jacob Chacko, M.D., MBA

4D Molecular Therapeutics, Inc.’s own tally for this item (“Elect Director: Jacob Chacko, M.D., MBA”): 28,579,453 for, 3,691,962 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 8,466,342 for, 278,781 withheld.

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

Description as filed by funds: Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Susannah Gray, MBA

4D Molecular Therapeutics, Inc.’s own tally for this item (“Elect Director: Susannah Gray, MBA”): 31,923,027 for, 348,388 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 8,673,884 for, 71,239 withheld.

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

Description as filed by funds: Approval, on an advisory, non-binding basis, of the compensation of the Company's named executive officers ("say-on-pay vote").

4D Molecular Therapeutics, Inc.’s own tally for this item (“3. On an advisory, non-binding basis, the named executive officers' compensation as disclosed in the Proxy Statement”): 31,841,967 for, 394,002 against — passed, per its Form 8-K filed June 20, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory, non-binding basis, the named executive officers' compensation as disclosed in the Proxy Statement.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 44 managers: 8,700,213 for, 44,910 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 112 managers: 24,081,872 for, 62,845 against, 96 not voted, 250,000 unknown, 18,353 1 year. Showing the 25 largest; see all in the interactive database.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 44 managers: 8,734,636 1 year, 10,487 3 year. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 108 managers: 21,162 for, 303 against, 96 not voted, 23,828,709 1 year, 33,737 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.

4D Molecular Therapeutics, Inc.’s own tally for this item (“2. The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025”): 38,380,552 for, 81,490 against — passed, per its Form 8-K filed June 20, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 8,743,871 for, 1,252 against.

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.